Stabilized CbpA Loop Polypeptides for Pneumococcal Vaccine Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Streptococcus pneumoniae are only 50% protective against pneumonia and lack immunogenicity in children under 2, and do not effectively prevent colonization in the nasopharynx or entry into the bloodstream, leaving patients vulnerable to most pneumococcal serotypes.
Innovation Solution
Development of pharmaceutical compositions including isolated polypeptides from the R2 domain of the CbpA protein, specifically the R21 and R22 domains, stabilized in a loop conformation using synthetic linkages, which are used in vaccines to enhance immunogenicity and protect against a wide range of pneumococcal infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines against Streptococcus pneumoniae are used, then some protection is provided, but the protective efficacy is only 50% and they lack immunogenicity in children under 2
Solution Approach 1:
The patent modifies the physical and chemical parameters of the vaccine antigen by stabilizing the CbpA protein in its native conformation using synthetic linkages (disulfide bonds). This parameter change in protein structure enhances immunogenicity and effectiveness, particularly in young children, while maintaining protection against multiple serotypes.
Solution Approach 2:
The vaccine comprises a composite structure where the CbpA protein is stabilized through synthetic disulfide bond linkages between specific cysteine residues. This composite approach combines the natural protein structure with engineered stabilizing elements to achieve enhanced immunogenicity and broader serotype coverage.
2Reliability
If current vaccines are administered, then partial protection is achieved, but they do not effectively prevent colonization in the nasopharynx or entry into the bloodstream
Solution Approach 1:
The CbpA-based vaccine provides universal protection against multiple pneumococcal serotypes by targeting a conserved protein structure rather than variable capsular polysaccharides. This multi-functional approach simultaneously prevents colonization, invasive disease, and bloodstream entry across diverse serotypes including 4, 6B, 9V, 14, 18C, 19A, and 23F.
3Reliability
If the CbpA protein is stabilized in native conformation using synthetic linkages, then immunogenicity is increased, but the device complexity increases
Solution Approach 1:
The CbpA protein is segmented into functional domains with specific cysteine residues targeted for disulfide bond formation. This segmentation approach allows strategic stabilization of key structural regions (R2 domain, repeat units) without requiring complete restructuring of the entire protein, thereby managing complexity while maintaining immunogenicity.
Data Source
AI summary
Compositions and methods for preventing and treating pneumococcal infections are provided. Compositions include novel polypeptides comprising an amino acid sequence corresponding to the R21 or R22 domain of CbpA or a consensus sequence of one of these domains, and variants and fragments thereof, wherein the polypeptide is stabilized in a desired conformation, particularly a loop conformation. The polypeptides of the invention may be engineered to comprise a first and a second cysteine residue, thereby resulting in the formation of a disulfide bond that stabilizes the polypeptide in the desired conformation. Alternatively, a polypeptide of the invention may be modified to create a synthetic linkage between a first and second amino acid residue present within the polypeptide, wherein the synthetic linkage stabilizes the polypeptide in the desired conformation. The polypeptides of the invention may further comprise an amino acid sequence for a T cell epitope. Compositions further include isolated nucleic acid molecules that encode the polypeptides of the invention, immunogenic compositions and vaccines comprising the disclosed polypeptides, and antibodies specific for these polypeptides.